Loading stock data…
Bio-Techne Corporation (TECH)
$71.60-0.17 (-0.24%)
Market ClosedLast close Jul 24
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bio-Techne Corporation in the Healthcare sector is trading at $71.60 with a market capitalization of $8.8B. Wall Street consensus targets $70.00 (12 analysts), implying a -2.2% move over the next 12 months. The stock is currently near its 52-week high of $72.16, remaining 21.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $311.42M↑ | $295.88M↑ | $286.56M↓ | $316.96M↑ | $316.18M |
| Gross Profit | $208.29M↑ | $191.28M↑ | $188.11M↓ | $198.81M↓ | $214.56M |
| Operating Income | $75.50M↑ | $54.46M↑ | $47.66M↓ | $116.69M↑ | $38.71M |
| Net Income | $51.05M↑ | $38.01M↓ | $38.19M↑ | -$17.68M↓ | $22.59M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.34%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.25%
Volume
Today's trading volume
2.06M
Recent News
What to Expect From Bio-Techne's Next Quarterly Earnings Report
Bio-Techne is scheduled to post its fourth-quarter results soon, and analysts project a single-digit earnings decline.
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry.
SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation
By Karen Roman SkylineDx said the FDA granted Breakthrough Device Designation to Merlin CP-GEP, the company’s gene expression profile test for risk assessment and clinical decision-making in patients with early-stage cutaneous melanoma. The Merlin CP-GEP is the first and only melanoma gene expression profiling test to have this FDA designation and to be included in […] The post SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation appeared first on ExecEdge.
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
The $11 Billion Reason TECH Stock Is Up Today
Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?